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background
 
Epidermal growth factor (EGF) is a potent mitogenic peptide produced by salivary
glands. We examined whether EGF enemas are an effective treatment for active left-sided
ulcerative colitis and ulceration limited to the rectum (proctitis).
 
methods
 
In a randomized, double-blind clinical trial conducted at Leicester Royal Infirmary,
12 patients with mild-to-moderate left-sided ulcerative colitis received daily enemas of
5 µg of EGF in 100 ml of an inert carrier and 12 received daily enemas with carrier alone
for 14 days. All also began to receive 1.2 g of oral mesalamine per day or had their dose
increased by 1.2 g per day. Patients were assessed clinically at 0, 2, 4, and 12 weeks and
by sigmoidoscopy and biopsy at 0, 2, and 4 weeks. The primary end point was disease
remission (defined by a St. Marks score of 4 or less without sigmoidoscopic evidence of
inflammation) at two weeks. Secondary end points were clinically significant improve-
ments in disease activity (defined by a decrease of more than 3 points in the St. Marks
score or the ulcerative colitis disease-activity index) at two and four weeks. Analyses
were performed according to the intention-to-treat principle.
 
results
 
After two weeks, 10 of the 12 patients given EGF enemas were in remission, as compared
with 1 of 12 in the control group (83 percent vs. 8 percent, P<0.001). At the 2-week as-
sessment, disease-activity scores, sigmoidoscopic score, and histologic scores were all
significantly better in the EGF group than in the placebo group (P<0.01 for all compar-
isons), and this benefit was maintained at 4 weeks and at 12 weeks.
 
conclusions
 
This study provides preliminary data suggesting that EGF enemas are an effective treat-
ment for active left-sided ulcerative colitis.
abstract
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lcerative colitis is a relapsing
 
disease of unknown cause characterized
by bloody diarrhea. Therapy usually in-
volves 5-aminosalicylates, which are of limited ben-
efit, with a response rate between 30 and 80 percent,
depending on the end point used,
 
1
 
 or corticoster-
oids such as prednisolone, although resistance and
dependency can become problematic with cortico-
steroids.
 
2
 
 Immunosuppressive drugs, such as aza-
thioprine, are beneficial but may have serious side
effects.
 
3
 
 New therapeutic approaches are therefore
needed.
Recombinant peptides are increasingly being
used for clinical purposes; for example, epoetin is
used for anemia related to renal failure. Human epi-
dermal growth factor (EGF) is a potent mitogenic
peptide produced by salivary and duodenal Brun-
ner’s glands,
 
4
 
 which stimulates several components
of the healing response.
 
5
 
 Preliminary studies in hu-
mans suggest that topical EGF enhances healing of
skin wounds
 
6
 
 and that systemic EGF is beneficial for
necrotizing enterocolitis in neonates.
 
7
 
 We therefore
examined the value of luminal (enema) EGF thera-
py for patients with active left-sided ulcerative coli-
tis or proctitis (ulceration limited to the rectum).
 
patients
 
Subjects were recruited from patients with active
colitis who attended the emergency colitis clinic
(thus including patients with acute relapse) and reg-
ular outpatient clinics at Leicester Royal Infirmary.
Entry criteria were a worsening of symptoms re-
quiring additional therapy and mild-to-moderate
disease, as indicated by a score of at least 5 on the
St. Marks index
 
8
 
 (in which a score of 12 indicates
the most severe disease) with a score of at least 1 (on
a scale of 0 [normal] to 3 [most severe inflamma-
tion]) on sigmoidoscopy.
 
8
 
 Patients were excluded if
they required hospitalization or intravenous corti-
costeroid therapy or if they were taking topical or
systemic corticosteroids, if their treatment had
changed in the three months before the study be-
gan, or if inflammation extended proximally to the
left side of the colon (i.e., beyond the splenic flex-
ure on fiberoptic endoscopy). Patients who had had
no changes in their immunosuppressive-therapy
regimen in the three months before recruitment to
the study were eligible.
 
study design
 
Patients were randomly assigned in a double-blind
fashion to receive an EGF or placebo enema for 14
days. A permuted-block design was used to achieve
equal numbers in each group. To ensure that all pa-
tients received an active treatment, all patients re-
ceived a pH-dependent, slow-release oral prepa-
ration of mesalamine (Asacol, GlaxoSmithKline).
Patients who were not taking mesalamine at recruit-
ment began to take 1.2 g per day, whereas patients
who were already taking mesalamine had their dose
increased by 1.2 g per day. Patients were assessed
clinically, sigmoidoscopically, and histologically
at the start of the study, at two weeks, and at four
weeks. At the two-week assessment, the enema
medication was discontinued but mesalamine ther-
apy was continued at the same dose. At the four-
week assessment, patients who were in remission
reverted to their original pretrial regimen (no treat-
ment or continued mesalamine), whereas those
with active disease had their medication increased
or changed according to clinical need; in most cas-
es, additional corticosteroid therapy or mesalamine
therapy or both were given. The four-week assess-
ment marked the end of the trial period, although
all patients underwent a final clinical review 12
weeks after entry. The study remained double-blind-
ed until after the 12-week review.
The study was approved by the Leicestershire
Research Ethics Committee. All patients gave writ-
ten informed consent.
 
enemas
 
Patients received daily enemas containing EGF or
carrier alone. Human recombinant EGF (Heber
Biotec, a commercial subsidiary of the Center for
Genetic Engineering and Biotechnology, Havana,
Cuba), expressed in 
 
Saccharomyces cerevisiae,
 
 compris-
es 60 percent EGF
 
1–52
 
 (the EGF protein, lacking one
terminal amino acid) and 40 percent EGF
 
1–51
 
 (the
EGF protein, lacking two terminal amino acids)
and has bioactivity equivalent to that of full-length
EGF
 
1–53
 
.
 
9
 
 The EGF enema consisted of 5 µg of EGF
in 100 ml of a degraded and modified gelatin carrier
solution (Haemaccel 3.5 percent, Beacon Pharma-
ceuticals). This dose of EGF was chosen because it
is similar to the concentration required to induce
the maximal restitution response in intestinal cell
lines.
 
10
 
 A two-week period of enema therapy was
chosen to maximize the likelihood of patients’ com-
pliance and because most standard therapies cur-
u
methods
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rently used, such as corticosteroid therapy, usually
have a positive result within this period. Placebo en-
ema consisted of modified gelatin carrier alone and
was indistinguishable from the EGF enema. Prelim-
inary studies involving the incorporation of [
 
3
 
H]thy-
midine into rat intestinal epithelium cells
 
10
 
 con-
firmed that the inert carrier did not influence cell
proliferation when it was given alone and that the
biologic activity of the EGF remained stable during
passage through the syringe and catheter, as previ-
ously described (data not shown).
 
9
 
Patients were taught to administer the enema
themselves in the supine position before going to
bed, using a 10-French rectal catheter attached to a
100-ml syringe. The patients gave themselves an en-
ema once a day for 14 days (they were instructed to
retain the preparation as long as possible) and then
lay on each side for 15 minutes to ensure maximal
contact of the enema preparation with the mucosa.
 
clinical scoring and definition 
of remission
 
At each assessment, patients completed a symptom
questionnaire and underwent a clinical examination
to generate three indexes of disease activity. The St.
Marks index
 
8
 
 and the ulcerative colitis disease-activ-
ity index
 
11
 
 provide an assessment of disease activity
based on a combination of symptoms, signs, and
sigmoidoscopic findings, with scores ranging from
0 to 12 and 0 to 22, respectively. In both cases, lower
scores mean less disease activity. We also analyzed
the data using a simplified symptom score, which
does not require information from sigmoidoscopy;
patients were given a clinical-severity score that
was based on an aggregate assessment of stool con-
sistency, visible blood in stool, and nocturnal defe-
cation, with a score of 0 or 1 for each, for a maximal
score of 3.
 
12
 
Remission was defined by a St. Marks score of
4 or less with no inflammation on sigmoidoscopy.
We also present the data using the ulcerative colitis
disease-activity index, for which we defined remis-
sion as a score of 0 or 1 (no blood in stool), and
using the simplified symptom score, for which we
defined remission as a score of 0.
 
12
 
 A clinical re-
sponse was defined as a decrease of more than three
points in the score on either the St. Marks index or
the ulcerative colitis disease-activity index.
 
blood tests
 
At each visit, 10 ml of venous blood was obtained for
the determination of the hemoglobin level, white-
cell count, platelet count, albumin level, and C-reac-
tive protein level.
 
sigmoidoscopic and histologic scoring
 
During the initial visit, all patients underwent a lim-
ited colonoscopic examination as far as the splenic
flexure, at approximately 50 cm, and always above
the upper limit of macroscopic disease. The second
and third examinations were limited to the distal
25 cm. The mucosal appearance was given a score
of 0, 1, 2, or 3, with 0 representing normal,
 
13
 
 and
three mucosal-biopsy specimens were obtained
from a point halfway along the inflamed section of
colon at the initial examination and at the same level
at subsequent examinations for histologic grading.
The biopsy specimens were fixed in formalin, sec-
tioned, stained with hematoxylin and eosin, and giv-
en a score of 0, 1, 2, or 3
 
8
 
; a score of 0 represented
normal histologic findings. Mucosal-biopsy speci-
mens were assessed in a blinded fashion by a single
investigator.
 
study end points
 
The primary end point of the study was disease re-
mission (as defined by a St. Marks score of 4 or less)
at two weeks. Secondary end points were clinically
significant improvements in the clinical and histo-
logic scores at two and four weeks.
 
statistical analysis
 
With 12 patients per group, the study had 80 percent
power to detect a significant difference in propor-
tions between a 10 percent rate of remission in the
placebo group and a 60 percent rate of remission in
the EGF group at a P value of 0.05 when the data
were evaluated with use of a chi-square test. Data
were analyzed in a blinded fashion according to the
intention-to-treat principle. The Wilcoxon signed-
rank test for paired samples was used to compare
differences within treatment groups, and the Mann–
Whitney U test was used to compare differences
between the groups. Fisher’s exact test was used
to compare remission rates in the two groups.
A planned interim analysis was conducted after 15
patients had completed the trial. All reported P val-
ues are based on two-sided t-tests.
 
characteristics of the patients
 
Twenty-four patients (12 of whom were men) were
recruited between March 1999 and January 2001.
results
Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at LONDON CHEST HOSP LIBRARY on July 28, 2008 . 
 n engl j med 
 
349;4
 
www.nejm.org july 
 
24, 2003
 
epidermal growth factor enemas for ulcerative colitis
 
353
 
Five patients in the placebo group and four in the
EGF group had proctitis. One patient in the EGF
group was taking azathioprine at recruitment, and
the dose had been unchanged for more than three
months before recruitment. No patients were re-
ceiving long-term topical mesalamine therapy at
the time of recruitment.
There were no significant differences between
the groups in any of the recorded base-line symp-
toms, signs, or hematologic, biochemical, sigmoid-
oscopic, or histologic characteristics (Table 1). The
median daily dose of mesalamine at both two and
four weeks was 2.4 g (range, 1.2 to 2.8) in both
groups. All 24 patients gave themselves the enema
and retained the solution for more than 45 minutes
per day for 14 days.
 
two-week assessment
 
At the end of the two weeks of enemas, all 12 pa-
tients in the EGF group had significant decreases
in the St. Marks score (P=0.005) (Table 2) and the
score on the ulcerative colitis disease-activity index
(P<0.001) (Fig. 1A), as compared with 2 of 12 pa-
tients in the placebo group. Remission as defined
by a St. Marks score of 4 or less was achieved in 10
of 12 patients in the EGF group, as compared with
1 of 12 in the placebo group (P<0.001). Remission
as defined by a score on the ulcerative colitis disease-
activity index of 0 or 1 was achieved in 4 of 12 pa-
tients in the EGF group, as compared with 0 pa-
tients in the placebo group (P=0.09). Remission as
defined by a simplified symptom score of 0 was
achieved in 10 of 12 patients in the EGF group, as
compared with 1 of 12 in the placebo group (P<
0.001) (Fig. 1B). In both groups, hematologic and
biochemical measurements were normal at the ini-
tial visit and remained so (Table 3). No side effects
were reported by any of the patients who were tak-
ing EGF.
Since only 6 of the 24 patients were not taking
mesalamine at the time of recruitment, formal sta-
tistical analysis of this subgroup was not possible.
However, the median St. Marks score improved by
6 points in the EGF group (three of three patients
were in remission) and by 4 points in the placebo
group (one of three were in remission).
Nine patients had proctitis. This number was
insufficient for formal subgroup analysis, although
the median St. Marks score improved by 6.5 points
in the EGF group (four of four patients were in re-
mission) and by 1 point in the placebo group (one
of five was in remission).
 
* EGF denotes epidermal growth factor, and UCDAI ulcerative colitis disease-
activity index.
† A score of 4 or less represented remission, with no inflammation on sigmoid-
oscopy.
‡ A score of 0 or 1 represented remission, with no visible blood in stool.
 
§ A score of 0 represented remission.
 
Table 1. Base-Line Characteristics of the Patients.*
Variable
Placebo Group
(N=12)
EGF Group
(N=12)
 
Male sex (no. of patients) 6 6
Age (yr)
Median
Range
36
20–56
44
21–64
Duration of colitis (mo)
Median
Range
72
4–144
60
6–192
Duration of exacerbation (wk)
Median
Range
3
1–10
4
1–6
Ongoing mesalamine therapy at entry
No. of patients
Median dose (g/day)
Dose range (g/day)
9
1.2
1.2–1.6
9
1.2
0.4–1.6
St. Marks score†
Median
Range
9
7–14
10
7–13
UCDAI score‡
Median
Range
9
7–11
9.5
7–12
Simplified symptom score§
Median
Range
2
1–3
2.5
1–3
Sigmoidoscopic score
Median
Range
2.5
2–3
3
2–3
Histologic score
Median
Range
3
1–3
3
2–3
Hemoglobin (g/dl)
Median
Range
13.2
12.0–15.2
13.3
11.4–15.8
White cells (¬10
 
–3
 
/mm
 
3
 
)
Median
Range
6.9
4.0–8.4
8.0
5.4–18
Platelets (¬10
 
–3
 
/mm
 
3
 
)
Median
Range
283
236–409
299
223–455
Albumin (g/liter)
Median
Range
43
39–52
44
36–49
C-reactive protein (mg/liter)
Median
Range
0
0–32
0
0–8
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Two patients in the placebo group were with-
drawn from the study at two weeks because of a
worsening of symptoms (diarrhea with blood) and
disease activity, although the investigators were un-
aware of the patients’ treatment assignments. This
represents failure of treatment, and these patients
were included in the denominator for all chi-square
tests. Since they were not assessed after their with-
drawal from the study, their data were not included
in calculations of the median values, ranges, and
statistical analyses (Wilcoxon and Mann–Whitney
tests) relating to disease activity. Significant im-
provements in clinical, sigmoidoscopic, and histo-
logic measurements were found in the EGF group
but not in the placebo group (Table 2).
 
four-week assessment
 
At four weeks, disease-activity scores in the EGF
group were significantly better than both pretreat-
ment values and the four-week values in the placebo
group (Table 2 and Fig. 1A). When remission was
defined according to the St. Marks score, 10 of 12
patients were in remission in the EGF group, as
compared with 3 of 12 in the placebo group (P=
0.012). When remission was defined according to
the score on the ulcerative colitis disease-activity in-
dex, 7 of 12 patients were in remission in the EGF
group, as compared with 1 of 12 in the placebo
group (P=0.03). When remission was defined ac-
cording to the simplified symptom score, 10 of 12
patients in the EGF group were in remission, as
compared with 3 of 12 in the placebo group (P=
0.01) (Fig. 1B).
 
12-week assessment
 
Since patients did not undergo sigmoidoscopy at
the 12-week assessment, we could not calculate the
St. Marks score or the score on the ulcerative colitis
disease-activity index. However, 8 of 12 patients
(67 percent) who had been treated with EGF and
who were in histologic remission at four weeks re-
mained in remission defined according to the sim-
plified symptom score, as compared with only 1 in
the placebo group (8 percent) (P=0.009). Nine of
the 12 patients in the placebo group (75 percent)
required oral or rectal corticosteroid treatment or
both: oral prednisolone and foam enemas in 2, pred-
nisolone foam enemas in 4, and prednisolone sup-
positories in 3. Four of the 12 patients in the EGF
group (33 percent) required rectal corticosteroid
treatment alone (prednisolone foam enemas) be-
tween 4 and 12 weeks.
 
subsequent review
 
We reviewed the patients’ records retrospectively to
determine the number who subsequently received
corticosteroid treatment. The decision to use corti-
costeroids was made by the attending physician on
the basis of his or her normal clinical criteria. By
6 months, 6 of the 12 EGF-treated patients had re-
quired local or systemic corticosteroids, and by the
last review, at a median of 16 months, 8 of the 12
had required local or systemic corticosteroids. By six
months, all the patients in the placebo group had
required local or systemic corticosteroids.
We found that once-daily EGF enemas induced rap-
id improvements in active left-sided ulcerative colitis
or proctitis when administered in combination with
oral mesalamine. The condition of all patients who
received EGF improved within two weeks, and 10 of
12 (83 percent) were in remission according to the
discussion
 
* Data were missing for two patients in the placebo group who were withdrawn 
from the study at two weeks because of worsening symptoms.
† A score of 4 or less represented remission, with no inflammation on sigmoid-
oscopy.
‡ P<0.01 for the comparison with the value before treatment.
§ A score of 0 represented remission, with no visible blood in stool.
 
¶No dysplasia was observed in any biopsy specimen at any time.
 
Table 2. Changes in Disease Activity among Patients Who Received 
Epidermal Growth Factor (EGF) or Placebo Enemas for 14 Days
in Addition to Mesalamine.
Variable Before Treatment At 2 Weeks At 4 Weeks*
 
median (interquartile range)
 
St. Marks score†
EGF
Placebo
P value
10  (8.75–10.25)
9  (9–10)
0.74
3  (2–4.25)‡
8.5 (6–11)
0.005
2  (1–3)‡
6.5 (3–8.75)
0.04
Simplified symptom 
score§
EGF
Placebo
P value
2.5 (2–3)
2  (2–2)
0.26
0  (0–0.75)‡
2  (1–2.75)
0.002
0  (0–0)‡
1.5 (0.25–2.75)
0.02
Sigmoidoscopic score
EGF
Placebo
P value
3  (2–3)
2.5 (2–3)
0.51
1  (1–1)‡
2  (2–3)
<0.001
1  (0–1.75)‡
2  (1–3)
0.04
Histologic score¶
EGF
Placebo
P value
3  (3–3)
3  (2–3)
0.26
2  (1–2)‡
3  (2–3)
0.002
1  (1–2)‡
2.5 (1.75–3)
0.05
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St. Marks score. In contrast, only two patients who
received placebo plus mesalamine had an improve-
ment, and only one of the two was in remission. Af-
ter 12 weeks there was no clinical evidence of early
relapse in patients in whom remission was achieved
with EGF therapy. Previous studies have reported
response rates to placebo of 16 to 52 percent,
 
14
 
 al-
though the number of patients who have a spon-
taneous full remission is probably much lower.
Mesalamine is a well-established agent for colitis
therapy that is superior to placebo,
 
15
 
 has dose-
dependent efficacy,
 
16
 
 and is useful when given both
topically and orally for distal colonic disease.
 
17
 
 The
lack of a major response to mesalamine therapy in
our study is probably related to the relatively small
additional oral dose used (1.2 g per day).
EGF is a 1207-amino-acid precursor
 
18
 
 that is
processed to a polypeptide of 53 amino acids
(EGF
 
1–53
 
). Circulating levels of EGF are low and
consist mostly of the EGF
 
1–52
 
 form,
 
19
 
 which is
bound to platelets and not readily available to the
gastrointestinal mucosa. Although EGF enters the
proximal gastrointestinal tract as EGF
 
1–53
 
, it is sus-
ceptible to progressive digestion as it proceeds dis-
tally. In acidic gastric juice, it is cleaved mainly to
EGF
 
1–49
 
, reducing its activity by 75 percent.
 
20
 
 Once
EGF enters the small intestine, it is rapidly digested
by pancreatic proteases within the lumen but may be
partially protected against digestion by the presence
of food.
 
21
 
 Under physiologic conditions, it is there-
fore likely that very little luminal EGF derived from
the upper intestine reaches the colon, and any oral-
ly administered EGF is unlikely to reach the distal
bowel unless it is protected from digestion. Admin-
istration of EGF as an enema has the advantage of
delivering the peptide to the injured area in a readily
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Figure 1. Changes in the Ulcerative Colitis Disease-Activ-
ity Index (Panel A) and the Simplified Symptom Score 
(Panel B) among Patients Who Received Epidermal 
Growth Factor or Placebo Enemas for 14 Days in Addi-
tion to Mesalamine.
 
Values in Panel A are expressed as the group medians 
and interquartile ranges. P values are for the comparison 
between groups. The asterisk denotes P=0.02 as com-
pared with the initial value. The daggers denote P<0.001 
as compared with the initial value. Scores for the ulcer-
ative colitis disease-activity index range from 0 to 22, with 
lower scores indicating less disease activity. The simpli-
fied symptom score was based on an aggregate assess-
ment of stool consistency, visible blood in stool, and 
nocturnal defecation,
 
12
 
 with a score of 0 or 1 for each and 
a maximal score of 3. A score of 0 represented remission.
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available, intact, active form. To ensure that ade-
quate active EGF reached the inflamed mucosa, we
administered an enema containing 100 times the
concentration of EGF found in gastric juice (500 ng
per liter),
 
20,22
 
 an amount sufficient to stimulate the
proliferation of intestinal cells in vitro.
 
10,19,20
 
EGF probably acts through several mechanisms.
It is a potent stimulant of cell migration (restitution)
and cell proliferation,
 
10,20
 
 both of which are impor-
tant in reestablishing epithelial continuity.
 
5
 
 EGF
also reduces injury and stimulates repair in animal
models of gastric, small intestinal, and colonic in-
jury,
 
9,20,23-25
 
 although the exact mechanisms of this
effect remain unclear. In our patients, it is likely that
EGF facilitated the reformation of the epithelial
barrier, and this in turn reduced the secondary in-
flammatory response to luminal antigens. Most
studies of the distribution of EGF receptors in the
normal human bowel suggest that they are restrict-
ed to the basolateral membranes.
 
26
 
 Our luminal
therapy probably stimulated repair by means of EGF
receptors exposed at the sites of injury, in keeping
with the role of EGF as a luminal surveillance pep-
tide.
 
5
 
 Other potential mechanisms include an in-
crease in the numbers of receptors
 
27
 
 and an alter-
ation in the distribution of receptors to include
apical membranes.
 
28
 
The cause of ulcerative colitis is unclear but prob-
ably involves an imbalance between aggressive fac-
tors and mucosal defense and repair. Since EGF is
important in repair mechanisms, a local or general-
ized defect in its production, its receptor, or the rate
of its destruction may be etiologic factors. Reduced
plasma levels of EGF are found in neonates with
necrotizing enterocolitis,
 
7
 
 and when the EGF re-
ceptor is deleted in mice,
 
29
 
 bowel ulceration results.
The use of recombinant peptides for so-called
hollow-organ gastrointestinal conditions is at a pre-
liminary stage.
 
30
 
 Many of the favorable outcomes
reported with the use of recombinant peptides in
animal models of gastrointestinal disease are seen
only if the peptides are administered before expo-
sure to the damaging agent, limiting their clinical
relevance. Systemic therapy with potent growth fac-
tors, such as EGF, could theoretically stimulate pre-
malignant lesions in distant organs. It is therefore
prudent to limit systemic therapy to life-threatening
conditions, as occurred in the case of a child with
necrotizing enterocolitis
 
7
 
 and in a child with con-
genital microvillous atrophy.
 
31
 
 Luminal therapy
overcomes many of these problems, since EGF will
only influence the growth and repair of the dam-
aged areas, where the basolateral receptors are ex-
posed. Although we found no colonic dysplasia in
this short-term study, serial biopsies of the affected
area in patients given exogenous EGF seem appro-
priate until potential safety issues have been ad-
dressed.
In summary, our finding that EGF enemas re-
duced disease activity and induced clinical remis-
sion expands on previous studies in vitro and in
animal models. To determine optimal doses and de-
livery methods, larger studies that directly compare
EGF with high-dose mesalamine or corticosteroids
appear to be warranted.
 
Supported by the Wellcome Trust and the Leicester Royal Infir-
mary Research fund.
Dr. Nightingale reports owning equity in GlaxoSmithKline. Dr.
Playford reports having received lecture fees from Lonza and grant
support from Scientific Hospital Supplies.
We are indebted to S. Ghosh, Imperial College, London, for sta-
tistical advice.
 
* Data were missing for two patients in the placebo group who were withdrawn 
from the study at two weeks because of worsening symptoms. There were no 
 
significant differences between or within the groups.
 
Table 3. Changes in Other Variables among Patients Who Received
Epidermal Growth Factor (EGF) or Placebo Enemas for 14 Days
in Addition to Mesalamine.*
Variable  Before Treatment At 2 Weeks At 4 Weeks
 
median (interquartile range)
 
Hemoglobin (g/dl)
EGF
Placebo
13.3 (12.7–14.4)
13.2 (12.4–14.8)
12.5 (11.7–13.7)
13.4 (12.7–14.2)
12.8 (12.2–13.6)
13.1 (12.4–14.2)
White cells 
(¬10
 
–3
 
/mm
 
3
 
)
EGF
Placebo
8.0 (7.1–12.9)
6.9 (5.6–8.1)
7.0 (6.2–11.8)
6.9 (6–7.5)
7.8 (6.0–10.4)
6.3 (5.8–7.5)
Platelets 
(¬10
 
–3
 
/mm
 
3
 
)
EGF
Placebo
299  (223–465)
283  (236–401)
335  (240–403)
285  (276–358)
315  (268–374)
305  (251–359)
Albumin (g/liter)
EGF
Placebo
44  (36–49)
43  (39–52)
42  (35–48)
42  (38–52)
43  (33–51)
43  (37–46)
C-reactive protein 
(mg/liter)
EGF
Placebo
0  (0–1.3)
0  (0–1)
0  (0–0)
0  (0–0)
0  (0–0)
0  (0–2.8)
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